NCT03397199Unknown2 期
A Phase II Clinical Trial of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the Therapy of Advanced Colorectal Cancer.
详细描述
Colorectal cancer is a common clinical gastrointestinal cancer. In addition to the early diagnosis of some patients, approximately 50% of patients have had distant metastases at the time of diagnosis. For patients with advanced colorectal cancer, systemic chemotherapy is the main treatment. We consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients. We designed the study to explore the possibility of apatinib for Advanced Colorectal Cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed the informed consent form prior to patient entry.
- •Histologically or cytologically diagnosed as metastatic colon or rectal adenocarcinoma patients.
- •The second-line standard regimen failed (disease progression) and the chemotherapy regimen included fluorouracil (5-FU / capecitabine / tioguanide), oxaliplatin and irinotecan from the last chemotherapy> 14 days.
- •≥ 18 and ≤ 70 years of age.
- •Eastern Cooperative Oncology Group(ECOG) performance status 0 or
- •Life expectancy of more than 3 months.
- •According to the solid tumor efficacy evaluation criteria RECISTv1.1 standards, at least one measurable lesions. If the previous treatment of local treatment (radiotherapy, radiofrequency, intervention, etc.) is the only focus of lesions, the request must have a clear imaging progress.
- •Adequate hepatic, renal, heart, and hematologic functions: ANC ≥1.5×109/L, PLT ≥ 100×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST≤ 2.5×ULN (or ≤ 5×ULN in patients with liver metastases), Serum Cr≤ 1.5×ULN, Cr clearance ≥ 60 mL/min.
- •Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 6 months after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 6 months after last dose of study drug.
排除标准
- •Uncontrollable hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, despite optimal medical therapy).
- •Poor glycemic control in diabetes.
- •Acute cerebral infarction, or recovery period <2 months.
- •A variety of factors that affect oral absorption (such as inability to swallow, nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).
- •Patients with gastrointestinal bleeding risk may not be included, including the following: (1) active peptic ulcer lesions and fecal occult blood (++); (2) history of melena and vomiting within 3 months；Fecal occult blood (+) is not an exclusion criterion.
- •Coagulation dysfunction (INR> 1.5, PT> ULN + 4s or APTT> 1.5 ULN), with bleeding tendency or ongoing thrombolysis or anti-blood coagulation treatment.
- •Patients whose routine urine tests indicate that urine protein ≥ ++ or verifies that the 24-h urine protein quantitation ≥ 1.0 g.
- •Pregnant or lactating women.
- •Cytotoxic drug treatment, radiotherapy within 2 weeks after treatment; had taken two or more oral targeted drugs.
- •Other malignant tumors, cutaneous basal cell carcinoma, and cervical cancer in situ in the past 5 years.
- •The investigators believe there is any condition that may harm the subject or result in the subject's inability to meet or perform the research requirements
- •Severe liver and kidney dysfunction (grade 4) patients should be excluded.
- •Any allergy to apatinib should be excluded.
- •Persons with a history of substance abuse who can not be abdicated or have mental disorders.
- •Previously used regurgitine is not an exclusion criterion.
- •According to the judgment of the researcher, there is a concomitant disease that seriously endangers the patient's safety or affects the patient in completing the study.
- •Patients who underwent surgery within 4 weeks prior to the start of treatment or who had major trauma or fractures. Or there is an unhealed wound before treatment.
- •Patients with severe heart disease such as grade III or above (NYHA standard) congestive heart failure, grade III or above (CCS standard) angina, or a history of myocardial infarction within 6 months prior to the start of treatment, or patients requiring medication Arrhythmia.
- •A brain metastasis, meningeal transfer.
- •Active HBV infection and refusal of regular antiviral treatment.
- •Active tuberculosis patients.
- •Participate in any drug or medical device clinical trial within 1 month before the test.
研究组 & 干预措施
Apatinib + S-1
Experimental
Apatinib + S-1
干预措施: Apatinib + S-1 (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: up to 2 year
From date of randomization until the date of first documented progression or date of death from any cause
次要结局
- Objective Response Rate (ORR)(up to 1 year)
- Overall survival(OS)(up to 2 year)
- Disease Control Rate (DCR)(up to 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLCNon Small Cell Lung CancerCombination ChemotherapyLung CancerApatinibNCT03201146West China Hospital48
Unknown
2 期
Study of Apatinib as the Maintenance Therapy in Advanced Lung AdenocarcinomaLung AdenocarcinomaNCT03376737Henan Cancer Hospital120
Unknown
2 期
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric CancerGastric CancerNCT02525237Qingdao Municipal Hospital30
尚未招募
2 期
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNSCLCNCT05932264Sun Yat-sen University60
Unknown
2 期
An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and GastricEsophagus Cancer, Stage IIIEsophageal Gastric Cardia Type MetaplasiaEsophagus Cancer, Stage IVNCT03285906Tianjin Medical University Cancer Institute and Hospital30